ASX Announcement
16 January 2025

Clarification - Annual Report Update

Advanced Health Intelligence Ltd (ASX:AHI) (**AHI** or **the Company**) refers to its update with respect to its Annual Report for the 2024 financial year (**2024 Annual Report**) that was released to the market on 14 January 2025 (**January Update**).

The 2024 Annual Report was due to be lodged by 30 September 2024. The Company confirmed on 25 November 2024 that the ongoing delay to the lodgement of the 2024 Annual Report was due to technical accounting issues. On 29 November 2024, AHI elaborated that the delay was caused by capital constraints and issues with respect to an independent investment valuation.

Although the Christmas closures referred to in the January Update have compounded AHI's ability to progress and finalise the audit of the Company's financial statements, the Company wishes to clarify that the delay in releasing the 2024 Annual Report prior to the previous target lodgement date of mid-late December is not due to these holiday closures.

The Company also wishes to provide further context to its statement in the January Update that it "is continuing" to work with the auditor - the Company confirms that it is continuing to work towards resolving the outstanding matters referred to above so that the audit can be completed. Subject to addressing these matters, AHI is aiming to finalise the audit and then release the 2024 Annual Report by early February 2025. The Company will continue to provide shareholders with any further material updates, including if there are any further delays.

The Chairman and CEO of Advanced Health Intelligence Ltd have approved this announcement.

For more information, please visit: www.ahi.tech

Simon Durack
Chief Finance Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

About Advanced Health Intelligence Ltd

AHI offers a cutting-edge, smartphone-based health risk identification solution that enables individuals to run their own comprehensive health assessments and risk stratification. Utilising smartphone sensor technology, individuals can efficiently conduct a single scan or a series of scans to identify established risk markers for various health conditions. The resulting data can then be shared with healthcare providers, insurers, employers, and government agencies, facilitating timely triage and appropriate care pathway allocation.

AHI's scientific research capability is dedicated to developing advanced data capture techniques, optimising data input signal quality, and continuously enhancing and validating AHI's solutions through rigorous scientific processes.

AHI has assembled a team of experts in machine learning, artificial intelligence, biomathematical modelling and systems biology, computer vision, clinical expertise, and medically trained data scientists to develop and deploy this cutting-edge risk assessment tool.

Over the past decade, AHI has been at the forefront of health-tech innovation, pioneering smartphones in digital-first healthcare. Our journey began with the groundbreaking development of the world's first on-device body dimensioning capability.

Since then, we have continued to evolve and adapt our solutions to meet the dynamic needs of health systems players, who are dedicated to delivering high-quality patient care and early detection of escalating health

conditions. AHI's patented technology has enabled us to push the boundaries of early detection through digital healthcare, offering a suite of modular solutions that are transforming the industry and offering earlier intervention opportunities.

Our comprehensive solutions encompass:

- Anthropometric and body composition analysis to identify obesity-related comorbidities, including diabetes risk stratification.
- Predictive modelling of blood biomarkers (including HbA1C, HDL-C, LDL-C) and 10-year cardiovascular risk estimation.
- Facial blood analysis technology to assess vital signs non-invasively and provide risk stratification for cardiovascular disease.
- Device-derived dermatological image analysis for identifying over 588 skin conditions across 134 categories, including melanoma detection.
- Atrial Fibrillation technology enables the detection of Atrial Fibrillation using a mobile device, allowing for early identification and monitoring of this common heart condition through a simple, non-invasive, and user-friendly smartphone-based solution.

AHI has developed a biometrically driven triage solution using only a smartphone. This solution enables the identification of health risks across populations and can inform individuals' direction to appropriate care pathways for proactive health management. The technology provides cost-effective health risk assessment access to billions of smartphone users worldwide, empowering these individuals to take charge of their health journey and improving health outcomes globally.

Advanced Health Intelligence Ltd.
ACN 602 111 115
Postal Address: PO Box 190, South Perth, WA 6951
Email: investors@ahi.tech